PubHawk
December 2020 PMID 33185144

Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation: Results of CONVERGE Clinical Trial.

David B DeLurgio, Karl J Crossen, Jaswinder Gill, Christopher Blauth, Saumil R Oza, Anthony R Magnano, Mark A Mostovych, Michael E Halkos, David R Tschopp, Faraz Kerendi, Tyler L Taigen, Christian C Shults, Manish H Shah, Anil B Rajendra, Jose Osorio

Full text PDF Download social card

Mentions

18
Peak: 3 in Nov 2020
across 3 sources since Nov 2020

Extended reach

107,896
potential audience

Total likes

103

Video views

2,292

Mentions per month

Nov 2020 – Jan 2025

Where it's discussed

  • X / Twitter12 posts
  • YouTube4 videos
  • News2 articles

AI synopsis

What people are saying

Discussions highlight the trial's successful results, such as the 67.7% effectiveness rate for the hybrid approach, and compare it favorably to traditional ablation techniques, emphasizing the potential for improved patient outcomes, which reflects a high level of interest and recognition of clinical significance.

AgreementModerate agreement

Most discussions support the positive outcomes reported in the trial, emphasizing the hybrid approach's efficacy.

InterestHigh interest

The posts show high interest, referencing specific data, trial results, and comparing techniques.

EngagementModerate engagement

Users engage by discussing the methodology, safety profiles, and clinical implications, suggesting moderate-depth interest.

ImpactModerate impact

The findings are considered impactful, with mentions of superior efficacy and potential shifts in clinical practice.

Abstract in brief

  • The Hybrid Convergent approach is a new minimally invasive technique for treating persistent atrial fibrillation (AF), designed to create more durable lesions than traditional endocardial catheter ablation (CA), addressing the limitations of CA in specific patient populations.
  • In the CONVERGE trial involving 153 patients, Hybrid Convergent showed a significantly higher rate of effectiveness in maintaining freedom from AF compared to CA at 12 months, with 67.7% versus 50.0% respectively, while also achieving better outcomes off antiarrhythmic drugs.
  • Safety profiles were favorable, with low rates of major adverse events (2.9% within 7 days) and no serious complications reported; thus
Read the full abstract

Top posts

Most liked on X and Bluesky
CircEP
@CirculationEP · X

CONVERGE RCT: Hybrid epi/endo convergent ablation has superior efficacy to catheter ablation alone for treating persistent/longstanding persistent AF @josoriomd @SaumilOzaMD @DavidBDeLurgio #AHAJournals #EPpeeps https://t.co/hrsyl9AiBo https://t.co/2XLL9xHUXj

Nov 17, 2020 · 29 likes · 7 shares · 8,523 followers View post →
Tolga Aksu, MD
@MDTolgaAksu · X

Results of CONVERGE trial was published in @CirculationEP primary effectiveness was achieved in 67.7% pts with Hybrid Convergent and 50.0%with CA(p=0.036) on/off previously failed AADs and in 53.5% versus 32.0%(p=0.0128) respectively off AADs. https://t.co/G9Rnwy3un3 https://t.co/l3oL1WAE4V

Nov 15, 2020 · 25 likes · 8,395 followers View post →
Heart Rhythm TV
@HeartRhythmTV · X

BREAKING: #HRStv host @DanielAlyeshmer is joined by @peterkistler3 and David B. De Lurgio, MD, FHRS for part II of their discussion. Covering the CONVERGE trial, data for transmural posterior wall ablation, and more. See more here #EPeeps ➡️ https://t.co/TJC0ynOlfD https://t.co/EOceeR6m0V

Jan 9, 2023 · 13 likes · 5 shares · 3,933 followers View post →
N. Tsukishima EP大学心電図検定学部試験対策科担任
@NaokiThukishima · X

#23jcs #AFablationの歴史と展望-09 新たなる希望(positive study) ＊PVI+MOM ethanol Infusion vs PVI+non-PVI ablation (49% vs 38%, p=0.04) JAMA. 2020;324:1620 =VENUS Trial= https://t.co/F0NKHC9auz ＊PVI+posterior wall ablation vs roofline (68% vs 50%, https://t.co/18piZSKGgf

Mar 25, 2023 · 4 likes · 15,899 followers View post →
忠犬外科医
@micscardiac · X

@Biz_zatukora そうなんですよ。 慢性心房細動に結構ポジティブなデータがでてました。 まあ、nがびっくりするほどちいさいですが笑。 でも最近の文献をみても、これからの主流になるのではないかとおもってます。 https://t.co/S4BdSh4Tld

Apr 28, 2021 · 2 likes · 3,521 followers View post →
Radcliffe Cardiology
@radcliffeCARDIO · X

✅ A review of hybrid convergent procedure for the treatment of persistent and long-standing persistent AF

May 19, 2023 · 1 like · 22,768 followers View post →

All mentions

AF Ablation Trials and Stroke Prevention Insights

This week, John Mandrola MD discusses important findings from recent AF ablation trials and emphasizes the significance of RCTs, particularly in the context of cryptogenic strokes. He reviews the comparative…

Medscape · Jan 31, 2025 603 views
Radcliffe Cardiology
@radcliffeCARDIO · X

✅ A review of hybrid convergent procedure for the treatment of persistent and long-standing persistent AF

May 19, 2023 · 1 like · 22,768 followers View post →
N. Tsukishima EP大学心電図検定学部試験対策科担任
@NaokiThukishima · X

#23jcs #AFablationの歴史と展望-09 新たなる希望(positive study) ＊PVI+MOM ethanol Infusion vs PVI+non-PVI ablation (49% vs 38%, p=0.04) JAMA. 2020;324:1620 =VENUS Trial= https://t.co/F0NKHC9auz ＊PVI+posterior wall ablation vs roofline (68% vs 50%, https://t.co/18piZSKGgf

Mar 25, 2023 · 4 likes · 15,899 followers View post →
Daniel Alyesh
@DanielAlyeshmer · X

RT @HeartRhythmTV: BREAKING: #HRStv host @DanielAlyeshmer is joined by @peterkistler3 and David B. De Lurgio, MD, FHRS for part II of their…

Jan 9, 2023 · 5 shares · 1,774 followers View post →
Heart Rhythm TV
@HeartRhythmTV · X

BREAKING: #HRStv host @DanielAlyeshmer is joined by @peterkistler3 and David B. De Lurgio, MD, FHRS for part II of their discussion. Covering the CONVERGE trial, data for transmural posterior wall ablation, and more. See more here #EPeeps ➡️ https://t.co/TJC0ynOlfD https://t.co/EOceeR6m0V

Jan 9, 2023 · 13 likes · 5 shares · 3,933 followers View post →
Radcliffe Cardiology
@radcliffeCARDIO · X

✅ A review of hybrid convergent procedure for the treatment of persistent and long-standing persistent AF

Oct 12, 2022 · 22,768 followers View post →
Dudu Companheiro
@DuduCompanheiro · X

RT @_10000feet: (…) Ablation to isolate the pulmonary veins (conducted by an electrophysiologist). https://t.co/R5ybvRZBjr Results were pub…

Jun 6, 2022 · 1 share · 1,236 followers View post →
10.000feet
@_10000feet · X

(…) Ablation to isolate the pulmonary veins (conducted by an electrophysiologist). https://t.co/R5ybvRZBjr Results were published in late 2020 in Circulation: Arrhythmia and Electrophysiology.

Jun 5, 2022 · 1 share · 289 followers View post →
Reina Tonegawa-Kuji MD, Ph.D, FACC
@ReinaTonegawa · X

このEpi-senseという心外膜側からの後壁隔離と、心内膜からのRF を組み合わせたConvergent approachは、RF単独と比較して18ヶ月後のSR維持率が高い（74%vs55%）。safety endpointの方は前者は102例中4例でeffusionありだがこれは仕方ないか。タンポは無しと主張しているが‥https://t.co/x3z8ZfPE5U

Apr 29, 2021 · 1 like · 6,593 followers View post →
忠犬外科医
@micscardiac · X

@Biz_zatukora そうなんですよ。 慢性心房細動に結構ポジティブなデータがでてました。 まあ、nがびっくりするほどちいさいですが笑。 でも最近の文献をみても、これからの主流になるのではないかとおもってます。 https://t.co/S4BdSh4Tld

Apr 28, 2021 · 2 likes · 3,521 followers View post →
Amin Al-Ahmad, MD
@aalahmadmd · X

RT @CirculationEP: CONVERGE RCT: Hybrid epi/endo convergent ablation has superior efficacy to catheter ablation alone for treating persiste…

Nov 17, 2020 · 7 shares · 9,854 followers View post →
CircEP
@CirculationEP · X

CONVERGE RCT: Hybrid epi/endo convergent ablation has superior efficacy to catheter ablation alone for treating persistent/longstanding persistent AF @josoriomd @SaumilOzaMD @DavidBDeLurgio #AHAJournals #EPpeeps https://t.co/hrsyl9AiBo https://t.co/2XLL9xHUXj

Nov 17, 2020 · 29 likes · 7 shares · 8,523 followers View post →
Tolga Aksu, MD
@MDTolgaAksu · X

Results of CONVERGE trial was published in @CirculationEP primary effectiveness was achieved in 67.7% pts with Hybrid Convergent and 50.0%with CA(p=0.036) on/off previously failed AADs and in 53.5% versus 32.0%(p=0.0128) respectively off AADs. https://t.co/G9Rnwy3un3 https://t.co/l3oL1WAE4V

Nov 15, 2020 · 25 likes · 8,395 followers View post →